Get started
Harvard Bioscience, Inc.Harvard Bioscience, Inc.Harvard Bioscience, Inc.

Harvard Bioscience, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

HBIO chart


Full chart

HBIO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪112.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.33 USD
Net income (FY)
‪−3.42 M‬ USD
Revenue (FY)
‪112.25 M‬ USD
Shares float
‪39.97 M‬
Beta (1Y)
1.21

Employees


Employees (FY)
416
Change (1Y)
−39 −8.57%
Revenue / Employee (1Y)
‪269.83 K‬ USD
Net income / Employee (1Y)
‪−8.21 K‬ USD

About Harvard Bioscience, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
James W. Green
Website
harvardbioscience.com
Headquarters
Holliston
Founded
1901
FIGI
BBG000C58Q08
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

HBIO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of HBIO is 2.57 USD — it has increased by 7.53% in the past 24 hours. Watch Harvard Bioscience, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Harvard Bioscience, Inc. stocks are traded under the ticker HBIO.
HBIO stock has risen by 7.08% compared to the previous week, the month change is a 6.64% rise, over the last year Harvard Bioscience, Inc. has showed a −38.81% decrease.
We've gathered analysts' opinions on Harvard Bioscience, Inc. future price: according to them, HBIO price has a max estimate of 7.00 USD and a min estimate of 5.50 USD. Watch HBIO chart and read a more detailed Harvard Bioscience, Inc. stock forecast: see what analysts think of Harvard Bioscience, Inc. and suggest that you do with its stocks.
HBIO reached its all-time high on Sep 4, 2001 with the price of 11.07 USD, and its all-time low was 1.30 USD and was reached on Nov 21, 2008. View more price dynamics on HBIO chart.
See other stocks reaching their highest and lowest prices.
HBIO stock is 9.36% volatile and has beta coefficient of 1.21. Track Harvard Bioscience, Inc. stock price on the chart and check out the list of the most volatile stocks — is Harvard Bioscience, Inc. there?
Today Harvard Bioscience, Inc. has the market capitalization of ‪112.08 M‬, it has increased by 4.70% over the last week.
Yes, you can track Harvard Bioscience, Inc. financials in yearly and quarterly reports right on TradingView.
Harvard Bioscience, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
HBIO earnings for the last quarter are −0.02 USD per share, whereas the estimation was 0.01 USD resulting in a −233.33% surprise. The estimated earnings for the next quarter are 0.04 USD per share. See more details about Harvard Bioscience, Inc. earnings.
Harvard Bioscience, Inc. revenue for the last quarter amounts to ‪21.97 M‬ USD, despite the estimated figure of ‪23.70 M‬ USD. In the next quarter, revenue is expected to reach ‪24.15 M‬ USD.
HBIO net income for the last quarter is ‪−4.80 M‬ USD, while the quarter before that showed ‪−2.93 M‬ USD of net income which accounts for −64.06% change. Track more Harvard Bioscience, Inc. financial stats to get the full picture.
No, HBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 416.00 employees. See our rating of the largest employees — is Harvard Bioscience, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Harvard Bioscience, Inc. EBITDA is ‪2.49 M‬ USD, and current EBITDA margin is 8.27%. See more stats in Harvard Bioscience, Inc. financial statements.
Like other stocks, HBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Harvard Bioscience, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Harvard Bioscience, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Harvard Bioscience, Inc. stock shows the sell signal. See more of Harvard Bioscience, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.